Moonlake Immunotherapeutics Earnings

Moonlake Immunotherapeutics’s revenue fell -100% since last year same period to $0Mn in the Q1 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated -100% fall in its revenue since last 3-months.

Moonlake Immunotherapeutics’s net profit fell -194.38% since last year same period to $-40.25Mn in the Q1 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated 11.73% jump in its net profits since last 3-months.

Moonlake Immunotherapeutics’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated -Inf% fall in its net profit margins since last 3-months.

Moonlake Immunotherapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.74 - a -3.18% fall from last quarter’s estimates.

Moonlake Immunotherapeutics’s earning per share (EPS) estimates for the current year stand at -0.74.

Moonlake Immunotherapeutics’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Moonlake Immunotherapeutics has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.